US Pharma MarketingSummit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trial
Akeso, Summit say ivonescimab hit the OS bar in China Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's…
After an interim overall survival result last year that shook investor confidence, Akeso has claimed victory Thursday with updated China-only Phase 3 data for its closely watched PD-1xVEGF bispecific in certain lung cancer patients.
Akeso ...
Source: Endpoints News